Actavis faces nine Digitek suits; N.J. court tosses out hormone case

> Actavis, the maker of recalled heart drug Digitek, faces at least nine federal lawsuits alleging the drug was dangerous and defective, including one suit over a patient who died while taking the drug. Report

> A New Jersey state court judge granted summary judgment against the claims made by a woman who alleged that Wyeth’s Prempro and Premarin, and Pfizer’s Provera, caused her breast cancer. Report

> Bayer, which withdrew the controversial cholesterol med Baycol seven years ago after it was linked to a severe muscle weakness that caused 31 deaths, has agreed to pay $18.5 million to settle shareholder litigation. Report

> Healthcare logistics firm Movianto GmbH and Identif, a specialist in the area of bio and nanotechnology, have created an anti-counterfeiting system that uses DNA coding to track distribution of the drug from the manufacturer to the patient. Report

> Amgen erroneously announced Monday that the Food and Drug Administration approved its Nplate treatment for a rare type of blood-platelet deficiency condition; the drug is still under review till July 23. Report

> Botox maker Allergan said Monday it completed the $150 million purchase of acne treatment gel Aczone from QLT USA Inc. Report

> A new survey of New Jersey's biotech industry has found that the drug development business is growing steadily. Report

> Researchers at Washington University in St. Louis have launched a nanotech company--called PixelEXX Systems--which intends to advance the use of nanoarrays in drug research. Report

> Richard Selden, the former CEO of Transkaryotic Therapies, has agreed to pay more than $1.1 million to settle claims he misled investors and improperly pumped up the value of the company's stock by inflating the potential of Replagal. Report

> Shares of Pharming spiked 24 percent on the news that fresh data demonstrated that its lead therapy Rhucin--developed in genetically modified rabbits as a therapy for hereditary angioedema--proved safe and effective in patients involved in ongoing open-label studies. Report

And Finally... The late Dr. Michael DeBakey's longevity drug? Work. Report

Suggested Articles

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?

Krystal Biotech has started on a new manufacturing facility for eventual commercial supply of gene therapies in its pipeline.

Chinese authorities have recommended trying AbbVie's HIV combo therapy Kaletra to treat the new coronavirus ravaging the country—and spreading fast.